Multiplex Assay Kit for Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) 
GOB4; HAG2; XAG2; AG2; PDIA17; HPC8; Anterior Gradient Protein 2; Protein Disulfide Isomerase Family A,Member 17; Secreted cement gland protein XAG-2 homolog
Overview
Properties
- Product No.CMC285Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryTumor immunityReproductive scienceBone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 91-98 | 94 |
| EDTA plasma(n=5) | 90-104 | 101 |
| heparin plasma(n=5) | 82-97 | 88 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 88-99% | 94-101% | 84-102% | 86-95% |
| EDTA plasma(n=5) | 83-94% | 79-90% | 90-98% | 78-103% |
| heparin plasma(n=5) | 92-99% | 88-96% | 91-102% | 96-104% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Anterior Gradient 2 (AGR2) ,etc. by CBA (Cytometric Bead Array) in the sample and corresponding value of MFI (Median Fluorescence Intensity). Flow Cytometer was used to determine and calculate the sample concentration.
Giveaways
Increment services
Citations
- Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinomaMetaPress: n7137r6271u54118
- Integrated Proteomic Profiling of Cell Line Conditioned Media and Pancreatic Juice for the Identification of Pancreatic Cancer BiomarkersPubMed: PMC3205865
- Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotypePubmed: 22911164
- Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9Pubmed: 24007603
- Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic CancerPubmed:25239611
- AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer DetectionPubMed: 25875093
- Serum AGR2 as a useful biomarker for pituitary adenomasS0303846717300045
- Identification, characterization and application of a new peptide against anterior gradient homolog 2 (AGR2)Pubmed:29937991
- Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy‑induced senescence escape34913074
- Proteome profiling of enzalutamide‐resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration‐resistant prostate cancerPubmed:35689436